- Poster presentation
- Open Access
Magnesium use on prophylaxis of vasospasm morbidity and the mortality rate in subarachnoid hemorrhage
Critical Care volume 13, Article number: P104 (2009)
We propose this study in order to reach two points: the clinical incidence of vasospasm morbidity, confirmed by CT; and the mortality of subarachnoid hemorrhage (SAH) patients in 28 days . It shows the comparison of a group of patients that used magnesium (Mg) (intervention, Group 1) with those that did not use Mg (control, Group 2).
After institutional approval and informed consent, a prospective, randomized, nonblind study was carried out between February and November 2008. The main goal of the study was to achieve a Mg serum concentration from 2.5 to 3.5 mg/dl, using a solution of Mg 2% (saline solution 5% 400 ml + MgSO4 10% 100 ml/24 hours), during the first 14 days of aneurysm rupture. Admission criteria: patients diagnosed with SAH and ΔT <96 hours. Exclusion criteria: patients with SAH and ΔT >96 hours.
In a previous study evaluation we analysed a total of 56 patients with (n = 26 in Group 1 and n = 30 in Group 2) (Tables 1 and 2). Main results: Group 1 – vasospasm frequency 26.9% (n = 7) and mortality 19.2% (n = 5) in 28 days; Group 2 – vasospasm frequency 46.7% (n = 14) and mortality 33.3% (n = 10) in 28 days.
According to the outcome, we can conclude that Group 1 obtained greater protection on the vasospasm incidence and decrease of mortality in comparison with Group 2. The P value was not significant due to a still small number of patients.
Schmid-Elsaesser R, et al.: Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. Neurosurgery 2006, 58: 1054-1065. 10.1227/01.NEU.0000215868.40441.D9
About this article
Cite this article
Macedo, S., Nuss, R., Lubanco, G. et al. Magnesium use on prophylaxis of vasospasm morbidity and the mortality rate in subarachnoid hemorrhage. Crit Care 13, P104 (2009). https://doi.org/10.1186/cc7268
- Public Health
- Mortality Rate
- Informed Consent
- Exclusion Criterion